Ascendis Pharma为其用于新诺沃诺迪斯的代谢性疾病治疗的TransCon技术颁发许可证。 Ascendis Pharma licenses its TransCon technology to Novo Nordisk for metabolic disease treatments.

Ascendis Pharma授予Novo Nordisk独家许可证,允许其利用TransCon技术开发治疗肥胖和2型糖尿病等新陈代谢疾病的治疗方法。 Ascendis Pharma has granted Novo Nordisk an exclusive license to use its TransCon technology for developing treatments for metabolic diseases such as obesity and type 2 diabetes. 该协议包括每月一次的 GLP-1 受体激动剂的先导项目，Ascendis 有资格获得高达 2.85 亿美元的付款，包括里程碑和特许权使用费。 The agreement includes a lead program for a once-monthly GLP-1 receptor agonist, with Ascendis eligible for up to $285 million in payments, including milestone and royalty payments. 预计交易将于2024年底结束。 The deal is expected to close by the end of 2024.